Interestingly, there was a highly significant correlation for concomitant detection of genomic aberrations to the R-ISS staging of patients, as 73% (8/11) patients in stage II/III but only 13% (1/8) patients in stage I showed tumor-specific variants in cfDNA.
← all excerpts
P829: GENOMIC PROFILING IN CFDNA COMPLEMENTS MOLECULAR DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA
1
—
—